Prader-Willi Syndrome Association | USA’s Post

In a recent contribution to European Pharmaceutical Manufacturer, SCTbio details the potential of leukapheresis #celltherapy to treat or even cure rare diseases, as well as how effective apheresis cell collection is needed to realise this potential. As experts in the field, with over 150 active apheresis cell collection centres, SCTbio is well placed to outline the key considerations for effective #apheresis cell collection: https://lnkd.in/eVpnzqAh The article was also written with valuable input from our partners Cyto-Care – specialists in providing advanced solutions for cell therapy and regenerative medicine. Through a collaborative and beneficial partnership, Cyto-care.eu and SCTbio will provide a reliable and accessible platform for collecting, characterizing, cryopreserving, and transporting #leukapheresis samples. Markus Dettke Klaus Fischer Miroslav Hlaučo #CGT

What are #Biosimilars? Glad you asked! Biosimilars create a broader range of cost-effective alternatives to reference biologics for healthcare providers. At Teva, we work relentlessly to transform every aspect of biologic drug development to improve speed and efficiency and maximize the value of biologics. This #GlobalBiosimilarsWeek, learn how biosimilars help bring affordable medicines to patients and savings to healthcare systems. Discover more here. #GlobalBiosimilarsWeek #biosimilars #TevaBiosimilarsUnlockingValue #Tevapharm #TeamTeva

Attention Pharmaceutical Drug Developers- Clinical Research for Liver Disease is about to get easier... with the latest innovations in non-invasive liver imaging from E-Scopics and the #Hepatoscope. We are excited to announce that #Hepatoscope is now being utilized at California Liver Research Institute. E-Scopics is proud to partner with CLRI and Dr. Edward Mena, to support MASH drug studies and accelerate screening #Hepatoscope.

This segment features .Laxminarayan Bhat, Ph.D., CEO of Reviva Pharmaceuticals (NASDAQ: RVPH) and Senior Life Sciences Analyst John Vandermosten. We cover a number of subjects related to schizophrenia medication and treatment. Starting with a review of biomarkers in development by others, we then look at biomarkers that will be used in the upcoming RECOVER 2 trial. The guests look at some of the methods of administration used for neuropsychiatric medicines. Other topics explored include treatment resistant patients, patent cliffs, pharma's search for new products, options for commercialization and expected timeline for RECOVER 2. https://lnkd.in/gxcHnN5v

Hematologic Malignancies Key Abstracts to watch during ASCO 2024. Leading companies such as Janssen Inc., Novartis, Genmab, Pfizer, Innate Pharma, and Sanofi are preparing to unveil their latest data and final analyses at the upcoming conference. The spotlight will be on key abstracts expected to make a lasting impact, generating significant interest and discussion throughout the event. In the last decade, the treatment options for hematologic malignancies have undergone significant expansion, notably with the advent of novel CAR T-cell therapies. These groundbreaking treatments have greatly enhanced patient outcomes. However, clinicians frequently encounter difficulties in identifying suitable candidates for these therapies, particularly among elderly individuals. Stay tuned with DelveInsight Business Research LLP for all the latest advancement in the Hematologic Malignancies set to be presented during the meeting @ https://lnkd.in/gd3txwQP #HematologicMalignancies #CARTTherapies #JanssenInnovates #NovartisResearch #GenmabAdvances #PfizerResearch #InnatePharmaUpdates #SanofiInnovation #ConferenceSpotlight #AbstractAnalysis #HematologyConference #ElderlyPatients #PersonalizedTherapy #ClinicalResearch #MedicalAdvancements

#MarketsWithBS | Pharma stocks surged after positive domestic and US market news. The 54th GST Council cut GST on cancer drugs—Trastuzumab Deruxtecan, Osimertinib, and Durvalumab—from 12% to 5%, boosting both patients and manufacturers. Details here👉 https://mybs.in/2dYtMND Shivam Tyagi #gst #markets #pharma #stockmarket

Coya CEO Howard Berman recently sat down with Pharmaceutical Executive's Don Tracy to discuss Coya 302 and its potential for the treatment of #ALS. Watch part 1 of the interview here and stay tuned for part 2: https://lnkd.in/eTGdiBAv $Coya #CoyaTherapeutics #neurodegenerative

Thoughts on this? >> Nuvalent's $350M offering; FDA lifts partial hold on Zentalis drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #biotech #productmarketing

We’re recruiting participants for an observational study focusing on Dupilumab’s effectiveness in treating Prurigo Nodularis 🩺. Sponsored by Sanofi in collaboration with Regeneron Pharmaceuticals, this research aims to capture real-world data to enhance our understanding of the treatment. 📊 Don’t miss this opportunity to help shape the future of dermatological treatments. 🌟 Contact us to check your eligibility for more information! See further details here: https://lnkd.in/gAbC4Aqs 🩺 Medcare Pharma: Your Way to Cure Contact us: ☎️ | 1-866-4-MEDICINE 📧 | info@medcarepharma.care 🌐 | https://lnkd.in/gA9pPUVR #PrurigoNodularis #waytocure #clinicaltrial #clinicalresearch #medicalresearch #clinicalstudies #clinicalstudy #healthcare #medcarepharma #researchstudies

Structure Therapeutics (GPCR) Steps Up Games in Weight-Loss Market (June 4, 11:00 UTC+8) GPCR reported significant advances in its new Phase 2a study of weight-loss drug GSBR-1290. The drug has clinically demonstrated 6.2% weight-loss efficiency in 12 weeks. Ongoing studies will focus on reducing side effects including nausea and vomiting. Notes: Eli Lilly (LLY)’s weight-loss drug ZepBound topped $517M in sales last quarter. Another notable competitor from the scene is Novo Nordisk (NVO) who recently launched multiple legal actions against counterfeit semaglutide, a key ingredient of its in-house weight-loss drug, Wegovy.